Abstract
Between 20% and 40% of patients with diabetes ultimately develop diabetic nephropathy, which in the US is the most common cause of end-stage renal disease requiring dialysis. Diabetic nephropathy has several distinct phases of development and multiple mechanisms contribute to the development of the disease and its outcomes. This Review provides a summary of the latest published data dealing with these mechanisms; it focuses not only on candidate genes associated with susceptibility to diabetic nephropathy but also on alterations in various cytokines and their interaction with products of advanced glycation and oxidant stress. Additionally, the interactions between fibrotic and hemodynamic cytokines, such as transforming growth factor β1 and angiotensin II, respectively, are discussed in the context of new information concerning nephropathy development. We touch on the expanding clinical data regarding markers of nephropathy, such as microalbuminuria, and put them into context; microalbuminuria reflects cardiovascular and not renal risk. If albuminuria levels continue to increase over time then nephropathy is present. Lastly, we look at advances being made to enable identification of genetically predisposed individuals.
Key Points
-
Microalbuminuria is not a predictor of nephropathy development in individuals with diabetes
-
Multiple mechanisms are operative in diabetes that are related to injury to the kidney and, in susceptible individuals, contribute to nephropathy development
-
Defects in nephrin and podocin are central to the development of macroalbuminuria and associated with nephropathy progression
-
Abnormally high concentrations of lipids contribute to β-cell injury and development of albuminuria
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Held PJ et al. (1991) The United States Renal Data System's 1991 annual data report: an introduction. Am J Kidney Dis 18: 1–16
Makino H et al. (1996) Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes 45: 488–495
Mauer SM et al. (1984) Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143–1155
Nielsen S et al. (1997) The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. J Intern Med 241: 133–141
Raile K et al. (2007) Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 30: 2523–2528
Remuzzi G et al. (2002) Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145–1151
Steinke JM et al. (2005) The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54: 2164–2171
Ziyadeh FN (2004) Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 15 (Suppl 1): S55–S57
Ichinose K et al. (2007) Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 27: 554–564
Raptis AE and Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109 (Suppl 2): S424–S437
Singh DK et al. (2008) Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 4: 216–226
Ziyadeh FN and Wolf G (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4: 39–45
Wolf G and Ziyadeh FN (1999) Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393–405
Wolf G and Ziyadeh FN (2007) Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106: 26–31
Hilgers KF and Veelken R (2005) Type 2 diabetic nephropathy: never too early to treat? J Am Soc Nephrol 16: 574–575
Nagai Y et al. (2005) Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 16: 703–711
Sharma K et al. (1999) Captopril-induced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 34: 818–823
Harris RD et al. (1991) Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 40: 107–114
Heilig CW et al. (1995) Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96: 1802–1814
Mishra R et al. (2005) High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int 67: 82–93
Lin CL et al. (2006) Wnt/β-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 17: 2812–2820
Chen ZJ et al. (2007) Expression of VEGF in kidney of diabetic rats [Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban 38: 633–636
Wolf G et al. (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626–1634
Mauer SM et al. (1983) The development of lesions in the glomerular basement membrane and mesangium after transplantation of normal kidneys to diabetic patients. Diabetes 32: 948–952
Friedman EA (1999) Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 14 (Suppl 3): S1–S9
Porte D Jr and Schwartz (1996) MW Diabetes complications: why is glucose potentially toxic? Science 272: 699–700
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820
Makita Z et al. (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836–842
Singh AK et al. (1998) Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 9: 802–810
Hogan M et al. (1992) Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90: 1110–1115
Cooper ME (1998) Pathogenesis prevention and treatment of diabetic nephropathy. Lancet 352: 213–219
Yamagishi S et al. (2007) Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 8: 952–959
Kunisaki M et al. (1994) Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 43: 1372–1377
Haneda M et al. (1995) Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diabetes Complications 9: 246–248
Tilton RG et al. (1989) Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 38: 1258–1270
Wilson DM and Luetscher JA (1990) Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 323: 1101–1106
Daneman D et al. (1994) Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. Kidney Int 46: 1154–1159
Nguyen G (2006) Renin/prorenin receptors. Kidney Int 69: 1503–1506
Ichihara A et al. (2006) Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 17: 1950–1961
Hohenstein B et al. (2006) Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69: 1654–1661
De Vriese AS et al. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993–1000
Sharma K and Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44: 1139–1146
Kanesaki Y et al. (2005) Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45: 288–294
Satchell SC et al. (2004) Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15: 566–574
Tsilibary EC (2003) Microvascular basement membranes in diabetes mellitus. J Pathol 200: 537–546
Baelde HJ et al. (2007) Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 71: 637–645
Flyvbjerg A et al. (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090–3094
Eremina V et al. (2006) Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 17: 724–735
Bortoloso E et al. (2004) Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol 150: 799–807
Janssen B et al. (2005) Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54: 2320–2327
Isaka Y et al. (1997) Application of gene therapy to diabetic nephropathy. Kidney Int Suppl 60: S100–S103
Benigni A et al. (2003) Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14: 1816–1824
Dai C et al. (2004) Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 15: 2637–2647
Navarro-Gonzalez JF and Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433–442
Jones S et al. (2001) Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. Kidney Int 59: 1739–1749
DiPetrillo K et al. (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284: F113–F121
DiPetrillo K and Gesek FA (2004) Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24: 352–359
Imig JD (2006) Eicosanoids and renal vascular function in diseases. Clin Sci (Lond) 111: 21–34
Pope JE et al. (1993) A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153: 477–484
Hao CM and Breyer MD (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71: 1105–1115
Hao CM and Breyer MD (2007) Roles of lipid mediators in kidney injury. Semin Nephrol 27: 338–351
Nishikawa T et al. (2007) Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes Res Clin Pract 77 (Suppl 1): S41–S45
Kiritoshi S et al. (2003) Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells—potential role in diabetic nephropathy. Diabetes 52: 2570–2577
Vasavada N and Agarwal R (2005) Role of oxidative stress in diabetic nephropathy. Adv Chronic Kidney Dis 12: 146–154
Suzuki D et al. (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10: 822–832
Mundel P and Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13: 3005–3015
Benigni A et al. (2004) Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 65: 2193–2200
Langham RG et al. (2002) Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45: 1572–1576
Doublier S et al. (2003) Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52: 1023–1030
Adler S (2004) Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int 66: 2095–2106
Trevisan R and Viberti G (1995) Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 126: 342–349
Pettitt DJ et al. (1990) Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33: 438–443
Imperatore G et al. (1998) Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 47: 821–830
Vardarli I et al. (2002) Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q223-23. Kidney Int 62: 2176–2183
Iyengar SK et al. (2007) Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes 56: 1577–1585
Movva S et al. (2007) Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with type 2 diabetes mellitus in Asian Indians. J Diabetes Complications 21: 237–241
Jeffers BW et al. (1997) Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 52: 473–477
Kunz R et al. (1998) Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 9: 1653–1663
Boright AP et al. (2005) Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54: 1238–1244
Acknowledgements
Charles P Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dronavalli, S., Duka, I. & Bakris, G. The pathogenesis of diabetic nephropathy. Nat Rev Endocrinol 4, 444–452 (2008). https://doi.org/10.1038/ncpendmet0894
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0894
This article is cited by
-
Amelioration of diabetic nephropathy in mice by a single intravenous injection of human mesenchymal stromal cells at early and later disease stages is associated with restoration of autophagy
Stem Cell Research & Therapy (2024)
-
Association of renal function with diabetic retinopathy and macular oedema among Chinese patients with type 2 diabetes mellitus
Eye (2023)
-
Circulating hsa-miR-221 as a possible diagnostic and prognostic biomarker of diabetic nephropathy
Molecular Biology Reports (2023)
-
Circ_0000064 promotes high glucose-induced renal tubular epithelial cells injury to facilitate diabetic nephropathy progression through miR-532-3p/ROCK1 axis
BMC Endocrine Disorders (2022)
-
Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus
BMC Endocrine Disorders (2022)